Primo N Lara

Title(s)Professor, Hematology and Oncology
SchoolSchool of Veterinary Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN
    NIH/NCI UM1CA186717Mar 28, 2014 - Feb 29, 2020
    Role: Co-Principal Investigator
    UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
    NIH K12CA138464Jan 1, 2009 - Jul 31, 2026
    Role: Principal Investigator
    Biochemical markers of bone turnover in metastatic prostate cancer
    NIH/NCI R01CA120469Aug 21, 2006 - Jun 30, 2012
    Role: Principal Investigator
    Barriers to accrual in cancer clinical trials
    NIH/NCI R21CA101724Aug 8, 2003 - Jul 31, 2006
    Role: Principal Investigator
    Cancer Center Support Grant P30
    NIH/NCI P30CA093373Jul 1, 2002 - Jun 30, 2021
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 Jul 16. Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, Adeniran A, Barata PC, Gulati S, Bergerot CD, Pruthi DK, Thompson IM, Lara PN, Lerner SP, Pal SK, Shuch BM. PMID: 39014969.
      View in: PubMed   Mentions:
    2. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Jul 02; JCO2302233. Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. PMID: 38954785.
      View in: PubMed   Mentions:    Fields:    
    3. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 Jul 01; 7(7):e2419966. Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN, Lerner SP, Thompson I, Agarwal N. PMID: 38980676; PMCID: PMC11234233.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024 Jun 25. Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, Drake CG, Signoretti S, Akgul M, Baniak N, Li-Ning E, Palmer MB, Emamekhoo H, Adra N, Kaimakliotis H, Ged Y, Pierorazio PM, Abel EJ, Bilen MA, Ogan K, Moon HH, Ramaswamy KA, Singer EA, Mayer TM, Lohrey J, Margulis V, Gills J, Delacroix SE, Waples MJ, James AC, Wang P, Choueiri T, Michaelson MD, Kapoor A, Heng DY, Shuch B, Leibovich BC, Lara PN, Manola J, Maskens D, Battle D, Uzzo R, Bratslavsky G, Haas NB, Carducci MA. PMID: 38942046.
      View in: PubMed   Mentions:    Fields:    
    5. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 May 28. Lara PN, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM, Ryan CW. PMID: 38811313.
      View in: PubMed   Mentions:    Fields:    
    6. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Mar 23. Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N. PMID: 38523017.
      View in: PubMed   Mentions:    Fields:    
    7. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer Prostatic Dis. 2024 Feb 29. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. PMID: 38424319.
      View in: PubMed   Mentions:    Fields:    
    8. Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023. Kidney Cancer. 2024; 8(1):23-24. Gulati S, Lara PN. PMID: 38420616; PMCID: PMC10897857.
      View in: PubMed   Mentions: 1  
    9. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. PMID: 38394781.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. JAMA Netw Open. 2023 08 01; 6(8):e2326546. Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MHA, Quinn DI, Lara PN, Thompson IM, Agarwal N. PMID: 37526936; PMCID: PMC10394570.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    12. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023 09 23; 402(10407):1043-1051. Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM, Lara PN. PMID: 37524096; PMCID: PMC10622111.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    13. Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer. Acta Pharm Sin B. 2023 Oct; 13(10):4273-4290. Chen Y, Tu MJ, Han F, Liu Z, Batra N, Lara PN, Chen HW, Bi H, Yu AM. PMID: 37799388; PMCID: PMC10547963.
      View in: PubMed   Mentions: 1  
    14. Preface. Curr Probl Cancer. 2023 Apr; 47(2):100971. Nardo L, Lara PN. PMID: 37330401.
      View in: PubMed   Mentions:    Fields:    
    15. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2024 Feb; 85(2):171-176. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. PMID: 37085425; PMCID: PMC10662935.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    16. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 02; 42(9):693-707. Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN, Evans CP, Hammock BD, Liu C. PMID: 36596844; PMCID: PMC9975039.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    17. Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. Kidney Cancer. 2022; 6(4):201-203. Gulati S, Lara PN. PMID: 36726555; PMCID: PMC9837794.
      View in: PubMed   Mentions: 1  
    18. The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 03; 14(23). Cacciamani GE, Barzi A, Eppler MB, Lara PN, Pan CX, Bhanvadia SK, Gill P, Aron M, Gill I, Sadeghi S. PMID: 36497466; PMCID: PMC9735798.
      View in: PubMed   Mentions: 1  
    19. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. Cancer Res. 2022 Nov 15; 82(22):4126-4138. Woo XY, Srivastava A, Mack PC, Graber JH, Sanderson BJ, Lloyd MW, Chen M, Domanskyi S, Gandour-Edwards R, Tsai RA, Keck J, Cheng M, Bundy M, Jocoy EL, Riess JW, Holland W, Grubb SC, Peterson JG, Stafford GA, Paisie C, Neuhauser SB, Karuturi RKM, George J, Simons AK, Chavaree M, Tepper CG, Goodwin N, Airhart SD, Lara PN, Openshaw TH, Liu ET, Gandara DR, Bult CJ. PMID: 36069866; PMCID: PMC9664138.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    20. ATR Inhibition in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2023 04; 21(2):203-207. Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. PMID: 36604210; PMCID: PMC10750798.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    22. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 02 01; 41(4):871-880. Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. PMID: 36256912; PMCID: PMC9901975.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    23. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    24. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 01 20; 41(3):640-650. Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. PMID: 35984996.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    25. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022; 6(2):105-107. Parikh M, Lara PN. PMID: 36212798; PMCID: PMC9490427.
      View in: PubMed   Mentions: 1  
    26. A Cancer Health Needs Assessment Reveals Important Differences Between US-Born and Foreign-Born Latinos in California. Front Oncol. 2022; 12:883200. Quino JE, Perez F, Perez A, Vang AP, Avendano L, Dang J, Chen MS, Arana AM, Rocha S, Nuno M, Lara PN, Fejerman L, Carvajal-Carmona LG. PMID: 35875145; PMCID: PMC9300947.
      View in: PubMed   Mentions: 1  
    27. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 10 01; 40(28):3301-3309. Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI. PMID: 35446628; PMCID: PMC9553390.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    28. Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2022 04 01; 28(7):1353-1362. Girardi DM, Niglio SA, Mortazavi A, Nadal R, Lara P, Pal SK, Saraiya B, Cordes L, Ley L, Ortiz OS, Cadena J, Diaz C, Bagheri H, Redd B, Steinberg SM, Costello R, Chan KS, Lee MJ, Lee S, Yu Y, Gurram S, Chalfin HJ, Valera V, Figg WD, Merino M, Toubaji A, Streicher H, Wright JJ, Sharon E, Parnes HL, Ning YM, Bottaro DP, Cao L, Trepel JB, Apolo AB. PMID: 35031545; PMCID: PMC9365339.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    29. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 03; 23(3):362-373. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, GALAHAD investigators. PMID: 35131040; PMCID: PMC9361481.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
    30. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 01; 20(1):71-90. Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. PMID: 34991070; PMCID: PMC10191161.
      View in: PubMed   Mentions: 139     Fields:    Translation:Humans
    31. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01; 7(10):1536-1543. Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN. PMID: 34436521; PMCID: PMC8391778.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    32. Defining the Optimal Management Strategy for Small Renal Masses. Kidney Cancer. 2021; 5(3):137-138. Dall'Era M, Lara PN. PMID: 34632170; PMCID: PMC8474519.
      View in: PubMed   Mentions:
    33. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    34. Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. JCO Glob Oncol. 2021 05; 7:671-685. Abreu D, Carvalhal G, Gueglio G, Tobia I, Garcia P, Zuñiga A, Meza L, Bengió R, Scorticati C, Castillejos R, Rodriguez F, Autran AM, Gonzales C, Gadu J, Nolazco A, Ameri C, Zampolli H, Langenhin R, Muguruza D, Machado MT, Mingote P, Yandian J, Clavijo J, Nogueira L, Clark O, Secin F, Rovegno A, Vilas A, Barrios E, Decia R, Guimarães G, Glina S, Pal SK, Rodriguez O, Palou J, Spiess P, Lara PN, Linehan WM, Pastore AL, Zequi SC. PMID: 33974442; PMCID: PMC8162501.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist. 2021 07; 26(7):560-e1103. Choueiri TK, Zakharia Y, Pal S, Kocsis J, Pachynski R, Poprach A, Nixon AB, Liu Y, Starr M, Lyu J, Owzar K, deShazo M, Lara P, Geczi L, Ho TH, Walsh M, Adams B, Robertson L, Darif M, Theuer C, Agarwal N. PMID: 33829609; PMCID: PMC8265348.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    36. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 03 18; 11(1):6377. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. PMID: 33737681; PMCID: PMC7973745.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    37. In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. Theranostics. 2021; 11(10):4858-4871. Li PC, Tu MJ, Ho PY, Batra N, Tran MML, Qiu JX, Wun T, Lara PN, Hu X, Yu AX, Yu AM. PMID: 33754032; PMCID: PMC7978307.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    38. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 02 20; 397(10275):695-703. Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN. PMID: 33592176; PMCID: PMC8687736.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    39. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 04 01; 27(7):1967-1973. Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. PMID: 33500355; PMCID: PMC8026618.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    40. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220; PMCID: PMC8140807.
      View in: PubMed   Mentions: 12     Fields:    
    41. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. PMID: 33583720; PMCID: PMC8637652.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    42. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021 06; 39(3):812-820. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. PMID: 33409898.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    43. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. Clin Cancer Res. 2021 03 01; 27(5):1391-1398. Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. PMID: 33262136; PMCID: PMC7925349.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    44. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clin Lung Cancer. 2021 01; 22(1):67-70. Riess JW, Frankel P, Shackelford D, Dunphy M, Badawi RD, Nardo L, Cherry SR, Lanza I, Reid J, Gonsalves WI, Kunos C, Gandara DR, Lara PN, Newman E, Paik PK. PMID: 33229301; PMCID: PMC7834952.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    45. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    46. Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684. Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN, Saraiya B, Pal SK, Stein MN, Mortazavi A. PMID: 32915679; PMCID: PMC7605393.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    47. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    48. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCells
    49. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 12; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    50. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precis Oncol. 2020; 4:442-465. Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH. PMID: 32903788; PMCID: PMC7446440.
      View in: PubMed   Mentions: 70     Fields:    
    51. Germline and somatic DNA repair gene alterations in prostate cancer. Cancer. 2020 07 01; 126(13):2980-2985. Dall'Era MA, McPherson JD, Gao AC, DeVere White RW, Gregg JP, Lara PN. PMID: 32315455.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    52. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10. Tenold M, Ravi P, Kumar M, Bowman A, Hammers H, Choueiri TK, Lara PN. PMID: 32239988.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    53. Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. J Clin Oncol. 2020 06 01; 38(16):1760-1762. de Vere White R, Lara PN, Black PC, Evans CP, Dall'Era M. PMID: 31951493.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. Nat Commun. 2019 10 11; 10(1):4621. Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, Xu J, Jiang Y, Zou H, Huang Z, Borowsky AD, Bold RJ, Lara PN, Li JJ, Chen X, Lam KS, To KF, Kung HJ, Fiehn O, Zhao R, Evans RM, Chen HW. PMID: 31604910; PMCID: PMC6789042.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    55. Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma. Urol Oncol. 2019 12; 37(12):947-954. de Almeida E Paula F, Bezerra SM, da Cunha IW, Munhoz GC, Abreu D, Lara PN, da Costa WH, Zéqui SC. PMID: 31473089.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319. Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH. PMID: 31420359.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    57. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 2019 10; 136:74-79. Morgensztern D, Karaseva N, Felip E, Delgado I, Burdaeva O, Dómine M, Lara P, Paik PK, Lassen U, Orlov S, Trigo J, Shomova M, Baker-Neblett K, Vasquez J, Wang X, Yan L, Mitrica I, DeYoung MP, Garrido P. PMID: 31446228.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    58. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. PMID: 31398279; PMCID: PMC6941667.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 10 10; 37(29):2682-2688. Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN. PMID: 31390274; PMCID: PMC7006847.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    60. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer. 2019 Aug 07; 3(2):111-118. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW. PMID: 31763512; PMCID: PMC6864417.
      View in: PubMed   Mentions: 5  
    61. A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry. Clin Lung Cancer. 2019 11; 20(6):477-483. Benjamin DJ, Klapheke A, Lara PN, Cress RD, Riess JW. PMID: 31375453; PMCID: PMC7179575.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    62. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852. Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. PMID: 31195180; PMCID: PMC6901020.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    63. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807. Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. PMID: 31152080; PMCID: PMC6738301.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    64. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2019 Nov; 5(6):927-929. Kim HL, Mayerson E, Lara PN, Messing E, Tangen C, Shuch BM, Vaishampayan U. PMID: 31103605; PMCID: PMC6858992.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    65. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precis Oncol. 2019; 3. Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N. PMID: 31218271; PMCID: PMC6583915.
      View in: PubMed   Mentions: 59     Fields:    
    66. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May; 15(15):1683-1695. Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. PMID: 30968729; PMCID: PMC6595543.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    67. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    68. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    69. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273; PMCID: PMC6421302.
      View in: PubMed   Mentions: 25  
    70. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. Kidney Cancer. 2019 Feb 05; 3(1):51-61. Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. PMID: 30854497; PMCID: PMC6400131.
      View in: PubMed   Mentions: 4  
    71. Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be. JAMA Oncol. 2019 02 01; 5(2):171-172. Lara PN, Evans CP. PMID: 30543365.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    72. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. Clin Lung Cancer. 2019 03; 20(2):74-81.e1. Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. PMID: 30528315.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    73. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 65     Fields:    
    74. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341. Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM. PMID: 30303516; PMCID: PMC6504933.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    75. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 09 01; 4(9):1197-1198. Gandara DR, Riess JW, Lara PN. PMID: 29902311.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    76. Editorial Comment. J Urol. 2018 11; 200(5):1003-1004. Stern M, Phillips JL. PMID: 30030970.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 272     Fields:    Translation:HumansCells
    78. Editorial Comment. J Urol. 2018 11; 200(5):1003. Dall'Era M, Lara PN. PMID: 30030973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clin Genitourin Cancer. 2018 12; 16(6):421-428.e1. Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN. PMID: 30166228; PMCID: PMC6450697.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    80. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747; PMCID: PMC6366813.
      View in: PubMed   Mentions: 312     Fields:    Translation:HumansCellsCTClinical Trials
    81. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018 10; 13(10):1560-1568. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. PMID: 29981927; PMCID: PMC6764748.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    82. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes. 2017; 2:27. Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL, Vogelzang NJ, Thompson IM, Moinpour CM. PMID: 29951640; PMCID: PMC5997724.
      View in: PubMed   Mentions: 2     Fields:    
    83. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treat Res Commun. 2018; 16:18-23. Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI. PMID: 31298998; PMCID: PMC6628720.
      View in: PubMed   Mentions: 4     Fields:    
    84. Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther. 2018 06; 365(3):494-506. Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. PMID: 29602831; PMCID: PMC5931433.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    85. Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. Kidney Cancer. 2017 Nov 27; 1(2):123-132. Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P. PMID: 30334014; PMCID: PMC6179121.
      View in: PubMed   Mentions: 15  
    86. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. Annu Rev Med. 2018 01 29; 69:209-221. Parikh M, Lara PN. PMID: 29144835.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    87. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. PMID: 29629426; PMCID: PMC5884164.
      View in: PubMed   Mentions: 7     Fields:    
    88. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. Yuh LM, Lara PN, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. PMID: 29382456; PMCID: PMC5798438.
      View in: PubMed   Mentions: 2  
    89. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 10; 112:165-168. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. PMID: 29191590.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    90. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. PMID: 28832978; PMCID: PMC5726867.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    91. Kidney Cancer: A New Forum for Impactful Scientific Interactions. Kidney Cancer. 2017 Jul 26; 1(1):1. Lara PN, Mulders PFA. PMID: 30333999; PMCID: PMC6179109.
      View in: PubMed   Mentions:
    92. Kidney Cancer Incidence in California: End of the Trend? Kidney Cancer. 2017 Jul 26; 1(1):71-81. Morris CR, Lara PN, Parikh-Patel A, Kizer KW. PMID: 30334007; PMCID: PMC6179112.
      View in: PubMed   Mentions: 3  
    93. The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup. Urol Pract. 2018 Jul; 5(4):305-310. Yap SA, Pugashetti N, Chandrasekar T, Dall'Era MA, Evans CP, Lara PN, deVere White RW. PMID: 37312295.
      View in: PubMed   Mentions:    Fields:    
    94. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer. 2017 12; 15(6):635-641. Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Quinn DI. PMID: 28579151; PMCID: PMC5734863.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    95. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget. 2017 May 09; 8(19):30742-30755. Jian C, Tu MJ, Ho PY, Duan Z, Zhang Q, Qiu JX, DeVere White RW, Wun T, Lara PN, Lam KS, Yu AX, Yu AM. PMID: 28415566; PMCID: PMC5458164.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    96. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017 07; 13(7):410-419. Wettersten HI, Aboud OA, Lara PN, Weiss RH. PMID: 28480903.
      View in: PubMed   Mentions: 242     Fields:    Translation:Humans
    97. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 04 01; 28(4):804-808. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN, Tannir NM. PMID: 28049139; PMCID: PMC5834088.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    98. A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2017 May; 79(5):923-932. Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN. PMID: 28352985; PMCID: PMC5403837.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    99. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. PMID: 28736761; PMCID: PMC5519297.
      View in: PubMed   Mentions: 12     Fields:    
    100. Clinical trial reporting: A new opportunity for cancer investigators. Cancer Treatment and Research Communications. 2017 Jan 1; 10:32. Lara LP. .
      View in: Publisher Site   Mentions:
    101. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    102. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May; 18(3):281-285. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. PMID: 28038979; PMCID: PMC5837026.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    103. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 03; 12(3):477-490. Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S. PMID: 27867002.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    104. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 11 01; 34(31):3717-3718. Riess JW, Lara PN, Gandara DR. PMID: 27601544; PMCID: PMC5477925.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    105. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. PMID: 27919627; PMCID: PMC5497702.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    106. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. PMID: 27650362; PMCID: PMC5360527.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    107. Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place? Clin Lung Cancer. 2016 07; 17(4):237-8. Daly ME, Lara PN. PMID: 27346548.
      View in: PubMed   Mentions:    Fields:    
    108. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. PMID: 27306686.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    109. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. PMID: 27019001; PMCID: PMC4892938.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    110. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol. 2016 Mar; 28(2):97-103. Parikh M, Riess J, Lara PN. PMID: 26844984; PMCID: PMC5139911.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    111. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. PMID: 26725184; PMCID: PMC4775366.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    112. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. PMID: 26498504; PMCID: PMC4789142.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    113. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10(10):1421-9. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, West HL, Lara PN, Gandara DR. PMID: 25719266.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 05; 373(19):1872-4. Quinn DI, Lara PN. PMID: 26406149; PMCID: PMC7526749.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    115. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. Gandara DR, Lara PN, Mack PC. PMID: 26215942.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    116. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072; PMCID: PMC4592395.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    117. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. PMID: 25979930; PMCID: PMC4862209.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimals
    118. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". J Thorac Oncol. 2015 May; 10(5):e36. Lara PN, Gandara DR, Redman MW. PMID: 25898968.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    119. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158; PMCID: PMC4586173.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    120. Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: a California Cancer Registry Study. Eur J Surg Oncol. 2015 May; 41(5):647-52. Gill A, Brunson A, Lara P, Khatri V, Semrad TJ. PMID: 25800934; PMCID: PMC4406634.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    121. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. PMID: 25739672; PMCID: PMC4452427.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    122. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J. 2015 Mar-Apr; 9(3-4):E204-7. Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall'Era MA. PMID: 26085880; PMCID: PMC4455640.
      View in: PubMed   Mentions: 5  
    123. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):144-8. Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN. PMID: 25667107; PMCID: PMC4430382.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    124. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. PMID: 25490004; PMCID: PMC4320001.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    125. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. Holland WS, Chinn DC, Lara PN, Gandara DR, Mack PC. PMID: 25323938; PMCID: PMC4562434.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    126. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. PMID: 25219358; PMCID: PMC4323674.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    127. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. PMID: 25091263; PMCID: PMC4318776.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    128. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat Rev Urol. 2014 Aug; 11(8):433-5. Evans CP, Lara PN. PMID: 25048863.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    129. Toward a common therapeutic framework in castration-resistant prostate cancer: a model for urologic oncology and medical oncology interaction. Urol Oncol. 2014 May; 32(4):380-2. de Vere White R, Lara PN. PMID: 24316022; PMCID: PMC4444361.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    130. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J. 2014 Oct; 14(5):424-31. Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJ, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ. PMID: 24709690.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    131. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014 Apr 01; 120 Suppl 7:1091-6. Chen MS, Lara PN, Dang JH, Paterniti DA, Kelly K. PMID: 24643646; PMCID: PMC3980490.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    132. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014 Sep 04; 33(36):4521-30. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, DeVere White RW, Gao AC, Evans CP. PMID: 24662833; PMCID: PMC4155805.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansAnimalsCells
    133. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. PMID: 24746995.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    134. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. PMID: 24616308; PMCID: PMC3970171.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansCellsCTClinical Trials
    135. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst. 2014 Apr; 106(4):dju013. Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. PMID: 24565955; PMCID: PMC3982883.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    136. Left behind? Drug discovery in extensive-stage small-cell lung cancer. Clin Lung Cancer. 2014 Mar; 15(2):93-5. Riess JW, Lara PN. PMID: 24529447; PMCID: PMC4184801.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    137. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014 Feb; 83(2):163-7. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. PMID: 24331409.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    138. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb; 32(1):178-87. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. PMID: 24242861; PMCID: PMC4560460.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    139. Papillary renal cell carcinoma: current progress and future directions. Clin Genitourin Cancer. 2014 Apr; 12(2):74-9. Twardowski PW, Mack PC, Lara PN. PMID: 24629521.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    140. Dasatinib and docetaxel in advanced prostate cancer. Lancet Oncol. 2013 Dec; 14(13):1248-9. Lara PN, Evans CP. PMID: 24211164.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    141. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733; PMCID: PMC4586161.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    142. Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry. Urology. 2013 Oct; 82(4):840-5. Pai A, Brunson A, Brown M, Pan CX, Lara PN. PMID: 24074980.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    143. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. PMID: 24013936; PMCID: PMC4562389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    144. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. PMID: 23910067; PMCID: PMC4122504.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    145. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. PMID: 23871417; PMCID: PMC4277263.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    146. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs. 2013 Jul; 24(6):636-40. Semrad TJ, Eddings C, Dutia MP, Christensen S, Lara PN. PMID: 23698253; PMCID: PMC4153755.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    147. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. PMID: 23470290.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    148. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. Mack PC, Gandara DR, Lara PN. PMID: 23253224.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    149. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. PMID: 23169517; PMCID: PMC4110249.
      View in: PubMed   Mentions: 192     Fields:    Translation:HumansCTClinical Trials
    150. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012; 17(9):1180-90. Javid SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. PMID: 22723506; PMCID: PMC3448411.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    151. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. PMID: 22745542; PMCID: PMC3383352.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    152. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. PMID: 22677432; PMCID: PMC4049356.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    153. Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am. 2012 May; 39(2):233-49, vii. Hu B, Lara PN, Evans CP. PMID: 22487765.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    154. Reply to E.S. Wang et al. Journal of Clinical Oncology. 2012 Mar 1; 30(7):761-762. McKeage MM, Lara LP. .
      View in: Publisher Site   Mentions:
    155. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer. 2012 Jun; 10(2):93-8. Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN. PMID: 22382008.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    156. Progress in personalizing chemotherapy for bladder cancer. Adv Urol. 2012; 2012:364919. Chang JS, Lara PN, Pan CX. PMID: 22400017; PMCID: PMC3287014.
      View in: PubMed   Mentions: 15  
    157. The hazards of randomized phase II trials. Ann Oncol. 2012 Jan; 23(1):7-9. Lara PN, Redman MW. PMID: 22190670.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    158. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan; 7(1):219-26. Pietanza MC, Lynch TJ, Lara PN, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA. PMID: 22011666.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    159. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. PMID: 21892109; PMCID: PMC3219834.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    160. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. PMID: 22015991; PMCID: PMC4131984.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    161. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. PMID: 21716143; PMCID: PMC3220078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    162. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011 Aug 01; 29(22):2965-71. Lara PN, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. PMID: 21709202.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    163. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN. PMID: 21644050; PMCID: PMC4562405.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    164. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. PMID: 21431345.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    165. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN, Devere White RW. PMID: 21412759.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    166. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara DR. PMID: 21119513.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    167. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar; 3(2):95-100. Semrad TJ, Gandara DR, Lara PN. PMID: 21789159; PMCID: PMC3126039.
      View in: PubMed   Mentions: 8  
    168. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177; PMCID: PMC3777729.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    169. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. PMID: 20975603.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    170. Medical oncology: Chemoradiotherapy for NSCLC-does a 'standard' exist? Nat Rev Clin Oncol. 2011 Jan; 8(1):5-6. Chen AM, Lara PN. PMID: 21102530.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    171. Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol. 2010 Nov; 5(11):1772-8. Suga JM, Nguyen DV, Mohammed SM, Brown M, Calhoun R, Yoneda K, Gandara DR, Lara PN. PMID: 20881638.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    172. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. PMID: 21028869; PMCID: PMC2987236.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    173. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. PMID: 20967484; PMCID: PMC3277821.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    174. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. PMID: 20888272; PMCID: PMC4572726.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    175. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. PMID: 20737417; PMCID: PMC2994945.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    176. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. PMID: 20646741; PMCID: PMC2952720.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    177. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. PMID: 20484019; PMCID: PMC2898710.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    178. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 20681067; PMCID: PMC6136060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR. PMID: 19839922.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    180. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. PMID: 19884861.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    181. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. PMID: 19884559; PMCID: PMC2793000.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    182. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 19900855.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    183. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol. 2009 Oct; 32(5):453-9. Van Veldhuizen PJ, Hussey M, Lara PN, Mack PC, Gandour-Edwards R, Clark JI, Lange MK, Crawford DE. PMID: 19487915; PMCID: PMC3394591.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    184. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. Sangha R, Lara PN, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. PMID: 19808190.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    185. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. PMID: 19494788.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    186. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. PMID: 19470925; PMCID: PMC2717760.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    187. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. Gandara DR, Lara PN, Mack P, Scagliotti G. PMID: 19443333.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    188. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. PMID: 19371909; PMCID: PMC2769926.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    189. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009 Jun 20; 27(18):3014-9. Le QT, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR. PMID: 19364954; PMCID: PMC2702233.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    190. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. PMID: 19349543; PMCID: PMC2684855.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCTClinical Trials
    191. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. PMID: 19240653; PMCID: PMC2716757.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    192. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. PMID: 19396016; PMCID: PMC3225398.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    193. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. Sangha R, Lara PN, Mack PC, Gandara DR. PMID: 19532012.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    194. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. PMID: 19204194; PMCID: PMC2668551.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    195. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. PMID: 19213668.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    196. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan; 4(1):87-92. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group. PMID: 19096312; PMCID: PMC3024911.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    197. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009 Feb; 181(2):512-6; discussion 516-7. Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S8949. PMID: 19100570; PMCID: PMC3394523.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    198. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol. 2008 Dec 01; 1:23. Levandovsky M, Harvey D, Lara P, Wun T. PMID: 19046460; PMCID: PMC2613392.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    199. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. Gandara DR, Lara PN, Natale R, Belani C. PMID: 18779609.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    200. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR, SWOG. PMID: 18779603; PMCID: PMC2653139.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    201. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer. 2008 Sep; 6(2):103-9. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ, Dakhil SR, Lara PN, Drelichman A, Hussain MH, Crawford ED. PMID: 18824433.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    202. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008 Jul 28; 168(14):1541-9. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN. PMID: 18663166.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    203. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. PMID: 18525299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    204. Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer. 2008 May; 9(3):141-3. Lara PN, Ramalingam SS. PMID: 18621622.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    205. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. Ramírez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. PMID: 18439749.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    206. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. PMID: 18381431.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    207. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. PMID: 18347165.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansAnimals
    208. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR, Southwest Oncology Group. PMID: 18202421.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    209. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008 Jan 01; 112(1):212-9. Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara DR, Davis SW, Wun T, Chen MS, Lara PN. PMID: 18008353.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    210. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. PMID: 18166843.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    211. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. Sangha R, Lara PN, Mack P, Gandara DR. PMID: 19419929.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    212. Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy. . 2008 Jan 1; 400-410. Huynh HM, Lara LP. .
      View in: Publisher Site   Mentions:
    213. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. PMID: 18090584.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    214. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    215. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. PMID: 18186959.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    216. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW. PMID: 17947488.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    217. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED, Southwest Oncology Group. PMID: 17664477.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    218. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 17671158.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    219. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55. Vansteenkiste J, Lara PN, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ, Edelman M. PMID: 17606973.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    220. Optimizing targeted therapy in patients with lung cancer with a performance status of 2. Clin Lung Cancer. 2007 Jul; 8(7):410-1. Lara PN, Davies AM. PMID: 17681092.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    221. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol. 2007 Aug; 25(4):393-9. Nelson EC, Evans CP, Pan CX, Lara PN. PMID: 17562051.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    222. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007 Jun 01; 25(16):2218-24. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC, National Cancer Institute. PMID: 17538166.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    223. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. PMID: 17508219.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    224. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):331-9. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. PMID: 17471291.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    225. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. PMID: 17440682.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    226. Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease. J Am Acad Dermatol. 2007 Oct; 57(4):683-9. Wadhera A, Maverakis E, Mitsiades N, Lara PN, Fung MA, Lynch PJ. PMID: 17433850.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    227. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007 May; 33(3):299-313. Nelson EC, Evans CP, Lara PN. PMID: 17329029.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    228. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. PMID: 17382026.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    229. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat Clin Pract Urol. 2007 Feb; 4(2):82-94. Nelson EC, Cambio AJ, Yang JC, Lara PN, Evans CP. PMID: 17287869.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    230. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007 Jan 20; 25(3):247-56. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN, Einhorn L, Mazumdar M, Bosl GJ. PMID: 17235042.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    231. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1707-13. Pan CX, Zhang H, Lara PN, Cheng L. PMID: 17181484.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    232. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. PMID: 17409985.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    233. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(1):6-14. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN, Evans CP. PMID: 17075603.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    234. Accrual issues in genitourinary cancer clinical trials. Urol Oncol. 2006 Sep-Oct; 24(5):379-83. Lara PN, de Vere White R. PMID: 16962485.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    235. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. PMID: 17026812.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    236. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara DR. PMID: 17026809.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    237. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20; 24(18):2828-35. Southwest Oncology Group, Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. PMID: 16782921.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    238. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer. 2006 May; 7 Suppl 4:S118-25. Ho C, Davies AM, Lara PN, Gandara DR. PMID: 16764752.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    239. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. PMID: 16800963.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    240. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 16622120.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    241. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. PMID: 16533781.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    242. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. Lara PN, Gandara DR, Natale RB. PMID: 16640809.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    243. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. PMID: 17409841.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    244. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come? Clin Lung Cancer. 2006 Jan; 7(4):232-4. Lara PN. PMID: 16512975.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    245. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR, Southwest Oncology Group Trial S0003. PMID: 16361616.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    246. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005 Dec 20; 23(36):9282-9. Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS. PMID: 16361626.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    247. Asian Americans and cancer clinical trials: a mixed-methods approach to understanding awareness and experience. Cancer. 2005 Dec 15; 104(12 Suppl):3015-24. Paterniti DA, Chen MS, Chiechi C, Beckett LA, Horan N, Turrell C, Smith L, Morain C, Montell L, Luis Gonzalez J, Davis S, Lara PN. PMID: 16247795; PMCID: PMC1810970.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    248. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. PMID: 16384543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    249. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer. 2005 Dec; 50S2:S17-S24. Rigas JR, Lara PN. PMID: 16551518.
      View in: PubMed   Mentions: 1     Fields:    
    250. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer. 2005 Dec; 50 Suppl 2:S17-24. Rigas JR, Lara PN. PMID: 16557670.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    251. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005 Dec 01; 23(34):8724-9. Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED, Southwest Oncology Group. PMID: 16314632.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    252. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. Davies AM, Lara PN, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. PMID: 16250929.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    253. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. Lara PN, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. PMID: 16250931.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    254. Recent developments in advanced urothelial cancer. Curr Opin Urol. 2005 Sep; 15(5):342-9. Chee KG, Cambio A, Lara PN. PMID: 16093860.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    255. Is the use of anything but MVAC justified in the evidence-based medicine era? Curr Opin Urol. 2005 Sep; 15(5):312-4. Ok JH, Cambio A, Lara PN, Evans CP. PMID: 16093854.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    256. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005 Aug 15; 11(16):5920-7. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. PMID: 16115934.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCTClinical Trials
    257. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 2005 Aug; 49(2):163-70. Mortenson MM, Schlieman MG, Virudachalam S, Lara PN, Gandara DG, Davies AM, Bold RJ. PMID: 16022909.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    258. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. PMID: 16000614.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    259. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15958629.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    260. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol. 2005 Jul; 56(1):39-45. Van Veldhuizen PJ, Faulkner JR, Lara PN, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED, Southwest Oncology Group. PMID: 15791454.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    261. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15711184.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    262. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. Lara PN, Twardowski P, Quinn DI. PMID: 15636683.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    263. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 15470214.
      View in: PubMed   Mentions: 1202     Fields:    Translation:HumansCTClinical Trials
    264. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    265. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. PMID: 15476595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    266. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15; 100(10):2125-31. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. PMID: 15139054.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    267. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. Davies AM, Lara PN, Lau DH, Gandara DR. PMID: 15094177.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    268. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. PMID: 19777702.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    269. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. PMID: 14871968.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    270. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. PMID: 14981579.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    271. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR, California Cancer Consortium. PMID: 14967075.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    272. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer. 2004 Jan 01; 100(1):82-8. Lara PN, Meyers FJ, Law LY, Dawson NA, Houston J, Lauder I, Edelman MJ. PMID: 14692027.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    273. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, Benfield JR. PMID: 14666039.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    274. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR, California Cancer Consortium. PMID: 14581348.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    275. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. PMID: 14555506.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    276. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 2):3938S-44S. DeNardo SJ, DeNardo GL, Yuan A, Richman CM, O'Donnell RT, Lara PN, Kukis DL, Natarajan A, Lamborn KR, Jacobs F, Siantar CL. PMID: 14506192.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    277. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. PMID: 12867067.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    278. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. PMID: 12886868.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    279. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003 Jun; 29(3):171-87. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. PMID: 12787712.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    280. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R, Southwest Oncology Group. PMID: 12743155.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    281. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 12667118.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    282. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. PMID: 12721762.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    283. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol. 2003 Feb; 45(2):177-90. Martel CL, Lara PN. PMID: 12604128.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    284. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. PMID: 12643004.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    285. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. PMID: 14720340.
      View in: PubMed   Mentions: 5     Fields:    
    286. Adjuvant therapy in completely resected malignant thymoma. Cancer Invest. 2003; 21(5):815-6. Lara PN. PMID: 14628439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    287. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002 Sep 01; 95(5):1009-15. Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. PMID: 12209684.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    288. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol. 2002 Jul; 70(3):191-4. Wang SE, Lara PN, Lee-Ow A, Reed J, Wang LR, Palmer P, Tuscano JM, Richman CM, Beckett L, Wun T. PMID: 12111764.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    289. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. PMID: 12170446.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    290. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002 May 15; 94(10):2584-9. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. PMID: 12173324.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    291. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 2002 May 15; 94(10):2797-8; author reply 2798-9. De Castro J, Feliu J, Casado E, Ordoñez A, González Barón M. PMID: 12173351.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    292. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara DR. PMID: 14720347.
      View in: PubMed   Mentions:    Fields:    
    293. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. Lara PN, Lau DH, Gandara DR. PMID: 12057087.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    294. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. PMID: 11894020.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    295. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. PMID: 12197222.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    296. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. PMID: 11740998.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    297. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001 Sep-Oct; 7(5):395-403. Liu HL, Gandour-Edwards R, Lara PN, de Vere White R, LaSalle JM. PMID: 11693898.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    298. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. PMID: 11488520.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    299. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001 Jul 01; 92(1):146-52. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. PMID: 11443620.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    300. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun; 28(3 Suppl 9):26-32. Gandara DR, Lara PN, Goldberg Z, Lau DH. PMID: 11441412.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    301. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res. 2001 Jun; 7(6):1561-8. O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ, Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ. PMID: 11410491.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCTClinical Trials
    302. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 244     Fields:    Translation:Humans
    303. Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):13-7. Gandara DR, Edelman MJ, Lara PN, Lau DH. PMID: 11301843.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    304. Improve survival with plasma exchange thrombotic thrombopenic purpura-hemolytic uremic syndrome. Am J Med. 2001 Feb 01; 110(2):156-7. Kaplan BS, Trachtman H. PMID: 11221612.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    305. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S5-9. Gandara DR, Lara PN, Goldberg Z, Roberts P, Lau DH. PMID: 11340902.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    306. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 2001 Jan 15; 19(2):442-7. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. PMID: 11208837.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    307. Evolution of combined modality therapy for stage III non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 5):35-41. Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. PMID: 10981289.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    308. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):26-30. Gandara DR, Lau DH, Lara PN, Edelman MJ. PMID: 10960942.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    309. Malignant thymoma: current status and future directions. Cancer Treat Rev. 2000 Apr; 26(2):127-31. Lara PN. PMID: 10772969.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    310. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med. 1999 Dec; 107(6):573-9. Lara PN, Coe TL, Zhou H, Fernando L, Holland PV, Wun T. PMID: 10625026.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    311. Molecular biology of prostate carcinogenesis. Crit Rev Oncol Hematol. 1999 Dec; 32(3):197-208. Lara PN, Kung HJ, Gumerlock PH, Meyers FJ. PMID: 10633849.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    312. Treatment options in androgen-independent prostate cancer. Cancer Invest. 1999; 17(2):137-44. Lara PN, Meyers FJ. PMID: 10071598.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    313. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8. Lara PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. PMID: 9788578.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    314. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). Invest New Drugs. 1998-1999; 16(4):347-51. Meyers FJ, Lew D, Lara PN, Williamson S, Marshall E, Balcerzak SP, Rivkin SE, Samlowski W, Crawford ED. PMID: 10426670.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    315. Salvage chemotherapy for recurrent invasive thymoma. Chest. 1997 Aug; 112(2):572-3. Musi M, Di Vito F, Rosti G. PMID: 9266913.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    316. Neovaginal malignant melanoma following surgery and radiation for vulvar squamous cell carcinoma. Gynecol Oncol. 1997 Jun; 65(3):520-2. Lara PN, Hearn E, Leigh B. PMID: 9190986.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    317. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest. 1996 Oct; 110(4):1115-7. Lara PN, Bonomi PD, Faber LP. PMID: 8874280.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans